ABIONYX Pharma SA (EPA:ABNX)

ABIONYX Pharma Statistics

Total Valuation

ABIONYX Pharma has a market cap or net worth of EUR 145.12 million. The enterprise value is 145.87 million.

Market Cap	145.12M
Enterprise Value	145.87M

Important Dates

The next estimated earnings date is Wednesday, December 24, 2025.

Earnings Date	Dec 24, 2025
Ex-Dividend Date	n/a

Share Statistics

ABIONYX Pharma has 34.68 million shares outstanding. The number of shares has increased by 11.34% in one year.

Current Share Class	34.68M
Shares Outstanding	34.68M
Shares Change (YoY)	+11.34%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	32.62%
Owned by Institutions (%)	4.38%
Float	20.58M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	33.55
PB Ratio	26.38
P/TBV Ratio	2,738.18
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-31.72
EV / Sales	33.72
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-39.82

Financial Position

The company has a current ratio of 1.40, with a Debt / Equity ratio of 0.75.

Current Ratio	1.40
Quick Ratio	1.30
Debt / Equity	0.75
Debt / EBITDA	n/a
Debt / FCF	-1.12
Interest Coverage	-65.79

Financial Efficiency

Return on equity (ROE) is -61.53% and return on invested capital (ROIC) is -26.26%.

Return on Equity (ROE)	-61.53%
Return on Assets (ROA)	-20.47%
Return on Invested Capital (ROIC)	-26.26%
Return on Capital Employed (ROCE)	-50.87%
Revenue Per Employee	84,824
Profits Per Employee	-90,176
Employee Count	51
Asset Turnover	0.30
Inventory Turnover	17.39

Taxes

In the past 12 months, ABIONYX Pharma has paid 8,000 in taxes.

Income Tax	8,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +223.92% in the last 52 weeks. The beta is 0.94, so ABIONYX Pharma's price volatility has been similar to the market average.

Beta (5Y)	0.94
52-Week Price Change	+223.92%
50-Day Moving Average	3.86
200-Day Moving Average	2.11
Relative Strength Index (RSI)	53.92
Average Volume (20 Days)	531,652

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ABIONYX Pharma had revenue of EUR 4.33 million and -4.60 million in losses. Loss per share was -0.13.

Revenue	4.33M
Gross Profit	769,000
Operating Income	-4.67M
Pretax Income	-4.59M
Net Income	-4.60M
EBITDA	-4.56M
EBIT	-4.67M
Loss Per Share	-0.13

Balance Sheet

The company has 3.38 million in cash and 4.12 million in debt, giving a net cash position of -743,000 or -0.02 per share.

Cash & Cash Equivalents	3.38M
Total Debt	4.12M
Net Cash	-743,000
Net Cash Per Share	-0.02
Equity (Book Value)	5.50M
Book Value Per Share	0.16
Working Capital	1.57M

Cash Flow

In the last 12 months, operating cash flow was -3.46 million and capital expenditures -207,000, giving a free cash flow of -3.66 million.

Operating Cash Flow	-3.46M
Capital Expenditures	-207,000
Free Cash Flow	-3.66M
FCF Per Share	-0.11

Margins

Gross margin is 17.78%, with operating and profit margins of -107.98% and -106.31%.

Gross Margin	17.78%
Operating Margin	-107.98%
Pretax Margin	-106.13%
Profit Margin	-106.31%
EBITDA Margin	-105.32%
EBIT Margin	-107.98%
FCF Margin	n/a

Dividends & Yields

ABIONYX Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.34%
Shareholder Yield	-11.34%
Earnings Yield	-3.17%
FCF Yield	-2.52%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ABIONYX Pharma has an Altman Z-Score of 2.5 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.5
Piotroski F-Score	1